Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jazz Pharmaceuticals PLC

100.34
-2.4400-2.37%
Post-market: 99.89-0.4500-0.45%17:35 EDT
Volume:610.83K
Turnover:61.14M
Market Cap:6.09B
PE:11.60
High:102.48
Open:102.11
Low:98.96
Close:102.78
Loading ...

Jazz Pharmaceuticals Completes Acquisition of Chimerix

THOMSON REUTERS
·
2 hours ago

Jazz Pharmaceuticals Completes Acquisition of Chimerix

PR Newswire
·
2 hours ago

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Zacks
·
Yesterday

JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?

Zacks
·
Yesterday

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Zacks
·
17 Apr

Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?

Zacks
·
17 Apr

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Zacks
·
15 Apr

Ironwood Shares Tank on Regulatory Update for Apraglutide

Zacks
·
15 Apr

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

Zacks
·
11 Apr

TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Zacks
·
10 Apr

Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last?

Zacks
·
10 Apr

Jazz Pharmaceuticals Price Target Maintained With a $210.00/Share by Needham

Dow Jones
·
10 Apr

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Simply Wall St.
·
09 Apr

Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case

Reuters
·
09 Apr

Jazz Pharmaceuticals Plc - to Record $145 Million Pre-Tax Charge in Q1 2025 - SEC Filing

THOMSON REUTERS
·
09 Apr

Jazz Pharmaceuticals- Co's Unit Enters Preliminary Class Settlement Agreement With Class of Indirect Xyrem Purchasers - SEC Filing

THOMSON REUTERS
·
09 Apr

AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs

Zacks
·
07 Apr

AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication

Zacks
·
05 Apr

SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases

Zacks
·
03 Apr

RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating

MT Newswires Live
·
03 Apr